Laboratory Medicine ›› 2017, Vol. 32 ›› Issue (12): 1137-1142.DOI: 10.3969/j.issn.1673-8640.2017.12.016
• Orginal Article • Previous Articles Next Articles
ZHAO Zhiyun, YUAN Wenhua, SONG Yunxiao
Received:
2017-05-24
Online:
2017-12-30
Published:
2018-01-10
CLC Number:
ZHAO Zhiyun, YUAN Wenhua, SONG Yunxiao. Performance of Mindray automatic H50 glycohemoglobin analyzer[J]. Laboratory Medicine, 2017, 32(12): 1137-1142.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2017.12.016
序号 | $\overline{x}$ | s | CV | 极差 |
---|---|---|---|---|
样本1 | 6.11 | 0.02 | 0.37 | 0.1 |
样本2 | 9.95 | 0.06 | 0.61 | 0.2 |
样本3 | 7.31 | 0.04 | 0.54 | 0.2 |
序号 | $\overline{x}$ | s | CV | 极差 |
---|---|---|---|---|
样本1 | 6.11 | 0.02 | 0.37 | 0.1 |
样本2 | 9.95 | 0.06 | 0.61 | 0.2 |
样本3 | 7.31 | 0.04 | 0.54 | 0.2 |
HbA1c | $\overline{x}$ | 批内精密度 | 批间精密度 | 室内精密度 |
---|---|---|---|---|
水平1 | 5.98 | 0.67 | 0.33 | 0.84 |
水平2 | 12.69 | 0.32 | 0.24 | 0.47 |
HbA1c | $\overline{x}$ | 批内精密度 | 批间精密度 | 室内精密度 |
---|---|---|---|---|
水平1 | 5.98 | 0.67 | 0.33 | 0.84 |
水平2 | 12.69 | 0.32 | 0.24 | 0.47 |
稀释比例 | 第1次 | 第2次 | 第3次 | $\overline{x}$ |
---|---|---|---|---|
4∶0 | 4.3 | 4.3 | 4.3 | 4.3 |
3∶1 | 7.6 | 7.5 | 7.5 | 7.5 |
2∶2 | 11.2 | 10.9 | 10.9 | 11.0 |
1∶3 | 14.3 | 14.0 | 14.0 | 14.1 |
0∶4 | 16.9 | 16.8 | 16.9 | 16.9 |
稀释比例 | 第1次 | 第2次 | 第3次 | $\overline{x}$ |
---|---|---|---|---|
4∶0 | 4.3 | 4.3 | 4.3 | 4.3 |
3∶1 | 7.6 | 7.5 | 7.5 | 7.5 |
2∶2 | 11.2 | 10.9 | 10.9 | 11.0 |
1∶3 | 14.3 | 14.0 | 14.0 | 14.1 |
0∶4 | 16.9 | 16.8 | 16.9 | 16.9 |
稀释比例 | 一次多项式线性预期值 | 三次多项式线性预期值 | 线性偏离绝对值(95%CI) | 相对偏差 |
---|---|---|---|---|
4∶0 | 4.42 | 4.29 | -0.13(-0.22~-0.04) | -3.0 |
3∶1 | 7.59 | 7.57 | -0.02(-0.12~0.08) | -0.3 |
2∶2 | 10.76 | 10.95 | 0.19(0.11~0.27) | 1.8 |
1∶3 | 13.93 | 14.14 | 0.21(0.10~0.31) | 1.5 |
0∶4 | 17.10 | 16.86 | -0.24(-0.33~-0.15) | -1.4 |
稀释比例 | 一次多项式线性预期值 | 三次多项式线性预期值 | 线性偏离绝对值(95%CI) | 相对偏差 |
---|---|---|---|---|
4∶0 | 4.42 | 4.29 | -0.13(-0.22~-0.04) | -3.0 |
3∶1 | 7.59 | 7.57 | -0.02(-0.12~0.08) | -0.3 |
2∶2 | 10.76 | 10.95 | 0.19(0.11~0.27) | 1.8 |
1∶3 | 13.93 | 14.14 | 0.21(0.10~0.31) | 1.5 |
0∶4 | 17.10 | 16.86 | -0.24(-0.33~-0.15) | -1.4 |
放置条件 | 天数 | HbA1c | 绝对偏差 |
---|---|---|---|
室温(18~24 ℃) | 1 | 6.32 | 0.00 |
2 | 6.31 | -0.01 | |
3 | 6.30 | -0.02 | |
4 | 6.29 | -0.03 | |
5 | 6.29 | -0.03 | |
6 | 6.31 | -0.01 | |
4 ℃ | 1 | 6.32 | 0.00 |
2 | 6.31 | -0.01 | |
3 | 6.31 | -0.01 | |
4 | 6.31 | -0.01 | |
5 | 6.31 | -0.01 | |
6 | 6.28 | -0.04 |
放置条件 | 天数 | HbA1c | 绝对偏差 |
---|---|---|---|
室温(18~24 ℃) | 1 | 6.32 | 0.00 |
2 | 6.31 | -0.01 | |
3 | 6.30 | -0.02 | |
4 | 6.29 | -0.03 | |
5 | 6.29 | -0.03 | |
6 | 6.31 | -0.01 | |
4 ℃ | 1 | 6.32 | 0.00 |
2 | 6.31 | -0.01 | |
3 | 6.31 | -0.01 | |
4 | 6.31 | -0.01 | |
5 | 6.31 | -0.01 | |
6 | 6.28 | -0.04 |
IFCC标准品 | HbA1c | 靶值 | 绝对偏差 |
---|---|---|---|
Level 1 | 5.10 | 4.99 | 0.11 |
Level 3 | 6.70 | 6.72 | -0.02 |
Level 5 | 8.50 | 8.44 | 0.06 |
Level 7 | 10.10 | 10.36 | -0.26 |
IFCC标准品 | HbA1c | 靶值 | 绝对偏差 |
---|---|---|---|
Level 1 | 5.10 | 4.99 | 0.11 |
Level 3 | 6.70 | 6.72 | -0.02 |
Level 5 | 8.50 | 8.44 | 0.06 |
Level 7 | 10.10 | 10.36 | -0.26 |
TG(g/L) | 低值样本 | 高值样本 | |||||||
---|---|---|---|---|---|---|---|---|---|
第1次测定值 | 第2次测定值 | $\overline{x}$ | 相对偏差 | 第1次测定值 | 第2次测定值 | $\overline{x}$ | 相对偏差 | ||
0 | 5.2 | 5.0 | 5.1 | 8.7 | 8.7 | 8.7 | |||
6.6 | 5.2 | 5.1 | 5.2 | 2.0 | 8.7 | 8.7 | 8.7 | 0.0 | |
13.2 | 5.1 | 5.0 | 5.1 | 0.0 | 8.7 | 8.6 | 8.7 | 0.0 | |
19.8 | 5 | 5.0 | 5.0 | -2.0 | 8.7 | 8.5 | 8.6 | -1.1 | |
26.4 | 5 | 5.0 | 5.0 | -2.0 | 8.5 | 8.5 | 8.5 | -2.3 | |
33.0 | 5 | 4.9 | 5.0 | -2.0 | 8.5 | 8.4 | 8.5 | -2.3 |
TG(g/L) | 低值样本 | 高值样本 | |||||||
---|---|---|---|---|---|---|---|---|---|
第1次测定值 | 第2次测定值 | $\overline{x}$ | 相对偏差 | 第1次测定值 | 第2次测定值 | $\overline{x}$ | 相对偏差 | ||
0 | 5.2 | 5.0 | 5.1 | 8.7 | 8.7 | 8.7 | |||
6.6 | 5.2 | 5.1 | 5.2 | 2.0 | 8.7 | 8.7 | 8.7 | 0.0 | |
13.2 | 5.1 | 5.0 | 5.1 | 0.0 | 8.7 | 8.6 | 8.7 | 0.0 | |
19.8 | 5 | 5.0 | 5.0 | -2.0 | 8.7 | 8.5 | 8.6 | -1.1 | |
26.4 | 5 | 5.0 | 5.0 | -2.0 | 8.5 | 8.5 | 8.5 | -2.3 | |
33.0 | 5 | 4.9 | 5.0 | -2.0 | 8.5 | 8.4 | 8.5 | -2.3 |
非结合胆红素(mg/L) | 低值样本 | 高值样本 | |||||||
---|---|---|---|---|---|---|---|---|---|
第1次测定值 | 第2次测定值 | $\overline{x}$ | 相对偏差 | 第1次测定值 | 第2次测定值 | $\overline{x}$ | 相对偏差 | ||
0 | 5.4 | 5.3 | 5.4 | / | 9.3 | 9.2 | 9.3 | / | |
40 | 5.4 | 5.4 | 5.4 | 0.0 | 9.2 | 9.2 | 9.2 | -1.1 | |
80 | 5.3 | 5.3 | 5.3 | -1.9 | 9.3 | 9.2 | 9.3 | 0.0 | |
120 | 5.4 | 5.4 | 5.4 | 0.0 | 9.2 | 9.2 | 9.2 | -1.1 | |
160 | 5.4 | 5.3 | 5.4 | 0.0 | 9.1 | 9.1 | 9.1 | -2.2 | |
200 | 5.4 | 5.4 | 5.4 | 0.0 | 9.1 | 9.2 | 9.2 | -1.1 |
非结合胆红素(mg/L) | 低值样本 | 高值样本 | |||||||
---|---|---|---|---|---|---|---|---|---|
第1次测定值 | 第2次测定值 | $\overline{x}$ | 相对偏差 | 第1次测定值 | 第2次测定值 | $\overline{x}$ | 相对偏差 | ||
0 | 5.4 | 5.3 | 5.4 | / | 9.3 | 9.2 | 9.3 | / | |
40 | 5.4 | 5.4 | 5.4 | 0.0 | 9.2 | 9.2 | 9.2 | -1.1 | |
80 | 5.3 | 5.3 | 5.3 | -1.9 | 9.3 | 9.2 | 9.3 | 0.0 | |
120 | 5.4 | 5.4 | 5.4 | 0.0 | 9.2 | 9.2 | 9.2 | -1.1 | |
160 | 5.4 | 5.3 | 5.4 | 0.0 | 9.1 | 9.1 | 9.1 | -2.2 | |
200 | 5.4 | 5.4 | 5.4 | 0.0 | 9.1 | 9.2 | 9.2 | -1.1 |
结合胆红素(mg/L) | 低值样本 | 高值样本 | |||||||
---|---|---|---|---|---|---|---|---|---|
第1次测定值 | 第2次测定值 | $\overline{x}$ | 相对偏差 | 第1次测定值 | 第2次测定值 | $\overline{x}$ | 相对偏差 | ||
0 | 5.4 | 5.4 | 5.4 | / | 9.2 | 9.2 | 9.2 | / | |
40 | 5.4 | 5.4 | 5.4 | 0.0 | 9.2 | 9.2 | 9.2 | 0.0 | |
80 | 5.4 | 5.4 | 5.4 | 0.0 | 9.2 | 9.2 | 9.2 | 0.0 | |
120 | 5.4 | 5.4 | 5.4 | 0.0 | 9.2 | 9.2 | 9.2 | 0.0 | |
160 | 5.4 | 5.4 | 5.4 | 0.0 | 9.2 | 9.2 | 9.2 | 0.0 | |
200 | 5.4 | 5.4 | 5.4 | 0.0 | 9.2 | 9.2 | 9.2 | 0.0 |
结合胆红素(mg/L) | 低值样本 | 高值样本 | |||||||
---|---|---|---|---|---|---|---|---|---|
第1次测定值 | 第2次测定值 | $\overline{x}$ | 相对偏差 | 第1次测定值 | 第2次测定值 | $\overline{x}$ | 相对偏差 | ||
0 | 5.4 | 5.4 | 5.4 | / | 9.2 | 9.2 | 9.2 | / | |
40 | 5.4 | 5.4 | 5.4 | 0.0 | 9.2 | 9.2 | 9.2 | 0.0 | |
80 | 5.4 | 5.4 | 5.4 | 0.0 | 9.2 | 9.2 | 9.2 | 0.0 | |
120 | 5.4 | 5.4 | 5.4 | 0.0 | 9.2 | 9.2 | 9.2 | 0.0 | |
160 | 5.4 | 5.4 | 5.4 | 0.0 | 9.2 | 9.2 | 9.2 | 0.0 | |
200 | 5.4 | 5.4 | 5.4 | 0.0 | 9.2 | 9.2 | 9.2 | 0.0 |
Glu(g/L) | 低值样本 | 高值样本 | |||||||
---|---|---|---|---|---|---|---|---|---|
第1次测定值 | 第2次测定值 | $\overline{x}$ | 相对偏差 | 第1次测定值 | 第2次测定值 | $\overline{x}$ | 相对偏差 | ||
0 | 5.3 | 5.3 | 5.3 | / | 9.9 | 9.9 | 9.9 | / | |
2 | 5.4 | 5.3 | 5.4 | 1.9 | 9.9 | 9.9 | 9.9 | 0.0 | |
4 | 5.3 | 5.4 | 5.4 | 1.9 | 9.8 | 9.9 | 9.9 | 0.0 | |
6 | 5.5 | 5.4 | 5.5 | 3.8 | 9.8 | 9.9 | 9.9 | 0.0 | |
8 | 5.3 | 5.3 | 5.3 | 0.0 | 9.8 | 9.9 | 9.9 | 0.0 | |
10 | 5.4 | 5.4 | 5.4 | 1.9 | 9.8 | 9.9 | 9.9 | 0.0 |
Glu(g/L) | 低值样本 | 高值样本 | |||||||
---|---|---|---|---|---|---|---|---|---|
第1次测定值 | 第2次测定值 | $\overline{x}$ | 相对偏差 | 第1次测定值 | 第2次测定值 | $\overline{x}$ | 相对偏差 | ||
0 | 5.3 | 5.3 | 5.3 | / | 9.9 | 9.9 | 9.9 | / | |
2 | 5.4 | 5.3 | 5.4 | 1.9 | 9.9 | 9.9 | 9.9 | 0.0 | |
4 | 5.3 | 5.4 | 5.4 | 1.9 | 9.8 | 9.9 | 9.9 | 0.0 | |
6 | 5.5 | 5.4 | 5.5 | 3.8 | 9.8 | 9.9 | 9.9 | 0.0 | |
8 | 5.3 | 5.3 | 5.3 | 0.0 | 9.8 | 9.9 | 9.9 | 0.0 | |
10 | 5.4 | 5.4 | 5.4 | 1.9 | 9.8 | 9.9 | 9.9 | 0.0 |
[1] | World Health Organization.Use of glycated haemoglobin(HbA1c) in the diagnosis of diabetes mellitus:abbreviated report of a WHO consultation[R]. Geneva:WHO,2011. |
[2] | Standards of medical care in diabetes-2016:summary of revisions[J]. Diabetes Care,2016,39(Suppl 1):S4-S5. |
[3] | 吴炯,邵文琦,周琰,等. 上海地区糖化血红蛋白一致性计划建立和结果初步评价[J]. 中华检验医学杂志,2012,35(4):370-372. |
[4] | 邵文琦,孙林,王蓓丽,等. 上海地区糖化血红蛋白一致性计划研究进展[J]. 检验医学,2015,30(9):948-952. |
[5] | 中华人民共和国医药行业标准. YY/T1246—2014 糖化血红蛋白分析仪[S]. 2014. |
[6] | Clinical and Laboratory Standards Institute. Evaluation of precision performance of quantitative measurement methods[S]. EP5-A2,CLSI,2004. |
[7] | Clinical and Laboratory Standards Institute. Evaluation of the linearity of quantitative measurement procedures[S]. EP6-A,CLSI,2003. |
[8] | Clinical and Laboratory Standards Institute. Method comparison and bias estimation using patient samples[S]. EP9- A3,CLSI,2013. |
[9] | LITTLE R. College of American Pathologists(CAP) GH5 survey data [EB /OL].(2015-08-15) [2017-07-05]. . |
[10] | 中华人民共和国医药行业标准.WS/T461—2015 糖化血红蛋白检测[S]. 2015. |
[11] | NATHAN D M,KUENEN J,BORG R,et al.Translating the A1C assay into estimated average glucose values[J]. Diabetes Care,2008,31(8):1473-1478. |
[12] | LENTERS-WESTRA E,SLINGERLAND R J.Three of 7 hemoglobin A1c point-of-care instruments do not meet generally accepted analytical performance criteria[J]. Clin Chem,2014,60(8):1062-1072. |
[1] | TAN Chunyan, ZHOU Ying, MO Zhijiang. Errors in Appendix B examples of WS/T 505—2017 and correction [J]. Laboratory Medicine, 2023, 38(6): 569-573. |
[2] | YANG Xiaodong, LI Quanle, PAN Qingqing, ZHOU Jing, XIE Yangmin, ZOU Jihua, SHEN Min, ZHANG Man. Establishment and performance evaluation of candidate reference measurement procedure for the determination of immunosuppressive drugs in human whole blood by ID-LC-MS/MS [J]. Laboratory Medicine, 2023, 38(3): 215-222. |
[3] | ZHENG Zhiyou, LI Xingzhao, XIE Yage. Changes and clinical significance of HbA1c,NT-proBNP,Hcy,SOD and TC levels in patients with diabetes cardiomyopathy [J]. Laboratory Medicine, 2023, 38(3): 282-286. |
[4] | LIU Congcong, LI Jiaping, ZHOU Hongwei. Performance evaluation of 2 mass spectrometry systems in clinical microbial identification [J]. Laboratory Medicine, 2022, 37(11): 1084-1088. |
[5] | QU Yuanqing, ZHAO Fan, YE Ailian, LI Lifeng, ZHAO Haitao, LI Huizhen, LIANG Zhuohui, LI Liang. Relationship between plasma omentin-1 level and metabolic clearance rate in type 2 diabetes mellitus patients [J]. Laboratory Medicine, 2022, 37(1): 28-31. |
[6] | YUE Daoyuan, CHEN Wei, LIAO Qing, YU Weiting, LI Huijun. Establishment and evaluation of Wuhan Glycohemoglobin Harmonization Program [J]. Laboratory Medicine, 2022, 37(1): 78-82. |
[7] | TIAN Yueru, WANG Jingjing, AI Fuqi, MA Yimin, WANG Bei, JIANG Xiaofei. Performance evaluation of Vitek 2 Compact AST-N334,AST-N335,AST-P639 Chinese antimicrobial susceptibility test cards [J]. Laboratory Medicine, 2021, 36(4): 417-423. |
[8] | Clinical Diagnosis and Laboratory Medicine Branch of China Maternal and Child Health Association. Expert consensus on establishment of standards for the performance evaluation of systems for whole blood C-reactive protein determination of Chinese children [J]. Laboratory Medicine, 2021, 36(12): 1201-1205. |
[9] | YUE Chaoyan, DUAN Chaohui, ZHANG Di, WEI Jie, LUO Xiaohong, ZHANG Qianlan, WU Yong, YING Chunmei. Performance evaluation of acridinium ester labeled direct chemiluminescence method for the detection of AMH and establishment of adult female AMH reference interval [J]. Laboratory Medicine, 2021, 36(1): 95-100. |
[10] | KANG Fengfeng, SHAN Zhiming, SONG Chao, XIA Xiaohua, CHEN Qian, LI Weixing. Comparability of glycated hemoglobin determination results with different determination systems using sigma metrics and robust algorithm [J]. Laboratory Medicine, 2020, 35(2): 168-172. |
[11] | SONG Jingchen, ZENG Jie, CHEN Tong, ZHANG Chuanbao, PAN Qi, LI Chuanbao, WU Quanying, TANG Dandan, WANG Qin. Performance evaluation of portable glucometers in a hospital of Beijing [J]. Laboratory Medicine, 2020, 35(11): 1186-1189. |
[12] | LIU Yang, ZHANG Zhiping, PENG Daorong, SONG Liuwei, GE Shengxiang, HAO Xiaoke, LIU Jiayun. Establishment and performance evaluation of chemiluminescent microparticle immunoassay for the determination of high concentration HbsAg [J]. Laboratory Medicine, 2020, 35(10): 1056-1061. |
[13] | WANG Xiao, MI Xianqiang. Construction of a 16 channel label-free electrochemical immunosensor for glycated hemoglobin A1c detection [J]. Laboratory Medicine, 2019, 34(9): 835-840. |
[14] | LIU Huiling, WANG Bing, ZHANG Ying, ZHU Jiawen, OUYANG Qinghui. Differences of sigma performance evaluation by using allowable total errors and biases from different sources [J]. Laboratory Medicine, 2019, 34(7): 648-650. |
[15] | LIU Wenbin, JU Yi, TANG Liping, WANG Meijuan, OU Yuanzhu, YU Xiaoxuan, LI Qing. IFCC Secondary Reference Measurement Procedure for 4 HbA1c determination systems [J]. Laboratory Medicine, 2019, 34(5): 443-446. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||